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The primary objective of this study was to determine whether participants who received an 
interactive electronic consent (EC) had a better understanding of a medical procedure 
(apheresis) compared to those who received the standard document (SD) consent.  The 
study was conducted with apheresis donors whose responses were used to determine if the 
EC facilitated better comprehension and retention of consent information by the study 
participants than by SD consenting methods. By comprehension, the goal was to have 
participants who can understand, summarize, or make judgments based on the content 
presented in the informed consent. By retention, the goal was to see if participants could 
recognize and select information presented in the informed consent.  
 
The two primary endpoints were measured using the Quality of Informed Consent (QuIC) 
index: knowledge of the various facets of the procedure, including the purpose of treatment 
and rights (Part A), and understanding of the informed consent items (Part B).  Secondary 
endpoints included the effect of EC vs. SD on decisional conflict, patient satisfaction, and 
anxiety, as well as preferences between the SD and electronic and whether participants 
who completed the EC consent were more likely to consent to the procedure. 
 
The specific aims of the study were: 
 
1) Obtain post-consent comprehension and understanding, anxiety, and decisional 
uncertainty in participants who completed SD and EC consent. 
2) Compare post-consent comprehension, retention, anxiety, and decisional 
uncertainty in participants who completed the SD and EC consents. 
a. Also, EC satisfaction with the delivery method was surveyed. 
 
The primary hypothesis was that participants who used the EC would perform better than 
those who used the SD informed consent across the following domains: 1) comprehension 
and retention; 2) decisional uncertainty; 3) anxiety, and 4) satisfaction. 
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BACKGROUND  
Over the last few decades, improving patient understanding of medical procedures has 
been a public health research priority and is a central component of improving care 
delivery. The current process for obtaining informed consent from patients has become 
increasingly recognized as obsolete, only marginally effective, and inefficient. In response, 
this study evaluated a newly developed electronic consent that automates the user 
interface as well as the content to improve the educational experience for patients and 
streamline the process. The electronic application is browser-based and consists of 
interactive text, illustrations, animations, schematics, and embedded videos to more fully 
educate patients so they make better-informed decisions. This process can be used to 
better inform patients regarding procedures, clinical trial participation and sample donation 
for biobanks. 
 
This project was designed to provide preliminary pilot data that will inform the design and 
conduct of larger initiatives to identify and develop more effective methods of delivering 
informed consent. 
 
The idea of optimizing the informed consent process was originally conceived by Dr. Sunil 
Patel when planning to engage in a breast cancer study (SWOG 212007) to determine the 
effectiveness of genetic testing certain types of lymph nodes.  In answering this question, 
the study would also answer the question of when or whether to use chemotherapy.  Given 
that this was an experimental approach, designing and explaining the study mechanics, risk, 
desired outcomes, and potential risks were particularly important.  The importance of 
conveying this information was matched only by the complexity of the science and its 
implications for breast cancer research and treatment. 
 
There was a need to develop a way to better educate clinicians and study participants on 
the nuances of the science.  The standard document form was too complex and required a 
lot of time to explain when training clinicians as well as when educating patients. Despite 
the time investment, there was still a fair amount of anxiety and confusion from patients. 
The challenge was to relate very complex information to patients and potential study 
participants in a different way while remaining compliant with informed consent 
regulations.  The goal and benefit were to inform and empower potential study participants 
to make an informed and comfortable decision to participate in the research.  Ultimately, 
the hope was to improve study accruals, comprehension, and the overall informed consent 
process. 
 
Compliance with current regulations doesn’t require validation of comprehension, 
measures of knowledge retention, or demonstration of low decisional anxiety.  From a 
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public health perspective, these are critical determinants of truly being certain that a 
patient or study participant is giving informed consent because they understand that to 
which they are consenting.  
 
Although the use of the informed consent process has been well described, the use of 
remote and mobile technologies in apheresis has been the subject of few inquiries to date. 
Most of the current research involves limited use of audio tools or static forms delivered on 
tablets. To our knowledge, no previous studies have investigated the role of a fully 
automated informed consent that utilized multiple forms of media and assessment 
instruments to measure comprehension and satisfaction.  
 
Informed Consent Process 
There are several key elements of the consent process that require information to be 
shared by the research team with the potential participant in a manner that can be 
adequately grasped and acted upon. The following steps illustrate the process for informed 
consent as it applies in clinical and research settings: 
 Development and delivery of research study or medical procedure 
information 
 Validation of comprehension of study or procedure information through 
discussion 
 The decision to or not to follow through with procedure or participate in the 
research study 
 Follow-up or commencement 
 
During the first step, the research team provides complete information about the 
procedure or research as well as participants' rights in a manner that can be understood by 
the patients and potential participants. Other aspects of the procedure or research study 
like the benefits of participation as well as the responsibility for care and complications 
must be carefully explained to patients and participants. In particular, they must be 
allowed to question the clinical or research team to clear up ambiguities and obtain 
additional information. 
The second step is critically important. The patient or participant must understand what is 
being asked. This can only happen if the information is presented in a manner that is 
simple yet conveys the key elements of the proposed research or medical treatment. 
Although this can be a difficult step, this interaction must occur when the potential patient 
or participant is calm. Participants may misunderstand the treatment or research if 
insufficient time is spent explaining it, too little time interacting with the research/clinical 
team, or their literacy levels have not been considered.  
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The next step in the process is when the patient or potential participant feels free to agree 
or not agree to take part in the procedure or research. Therefore, not only must the 
participant understand the project or medical treatment, but they must also be competent 
to give his or her consent.  This is in part the motivation for reconsidering the most 
effective ways to deliver informed consent. 
The electronic informed consent (EC) includes several different ways of obtaining informed 
consent.  Although the EC allows for a more contemporary and flexible method of delivery, 
the absence of paper or reduction of face-to-face contact has added to concerns of 
complications in the consent process.  The most common concerns are: 
 Ensuring comprehension 
 Ensuring all of the necessary content 
 Securing and protecting personal information 
 
This study aimed to test the enhanced version of the electronic consent prototype 
incorporating new decision-support features including multimedia components, to create a 
novel, electronic consent (EC). This study was conducted with donors who were candidates 
for apheresis to determine if the prototype facilitates better comprehension and retention 
of consent information by the study participants than by standard consenting methods. By 
comprehension, the goal was to have participants who could understand, summarize, or 
make judgments based on the content present in the informed consent. By retention, the 
goal was to see if participants could recognize and select information presented in the 
informed consent. There are other potential benefits of EC such as efficiency, positive 
accrual impact, and better participant experience that are also important, but not the focus 
of this study.  The information obtained from the study also addresses regulatory obstacles 
to implementing innovative consent processes and identify questions for subsequent 
studies comparing EC to traditional paper or consent. 
 
Overview 
The informed consent (IC) process for apheresis is of critical importance for two reasons: 1) 
the recognition of patient protections as an individual right and societal duty, and 2) the 
dependence of medical progress on patient participation in living saving procedures. 
Strategies to improve the IC process must, at a minimum, preserve or enhance human 
subject protections while, ideally, addressing barriers to making medical decisions about 
procedures. 
 
Guidance from the FDA states "When obtaining informed consent, informed consent must 
be documented by a signed and dated written consent form except under two specific 
circumstances, as described in FDA's regulations at 21 CFR 56.109(c) (FDA, 201628) (21 CFR 
50.27.) When written informed consent is required, the use of electronic, including digital, 
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signatures is permitted under FDA's regulations, provided it complies with applicable 
regulations" (FDA, 201629). 
 
Within the bioethics literature, authors have defined the following elements as essential for 
IC: 1) competence, 2) disclosure, 3) understanding, 4) voluntariness, and 5) consent. In 
terms of regulatory requirements (45 CFR 46.116) 12, there are 8 required elements of IC 
and 6 provisional elements. Thirteen of 14 federally mandated elements are most 
accurately mapped to the ethical concept of disclosure, with the remaining element 
mapping to voluntariness. Assessment of competence and documentation of consent is also 
well-established elements of the existing IC process. Aside from requirements regarding the 
use of simplified language, federal regulations do not require specific mechanisms to 
facilitate or ensure patient understanding of clinical procedures.  
 
FDA guidance stipulates that electronic consents be "trustworthy, reliable, and generally 
equivalent to handwritten signatures executed on paper when they capture the signature of 
the subject or the subject's LAR (e.g., an encrypted digital signature, electronic signature 
pad, voice print, and digital fingerprint). However, the FDA does not mandate a specific 
method of electronic signature. IRBs should consider applicable issues such as how the 
electronic signature is created if the signature can be shown to be legitimate and if the 
consent or permission document can be produced in hard copy for review by the subject 
upon request." (FDA, 2015). 
 
Though the intent and format of the traditional consent process meet regulatory 
requirements, there remain important concerns about the quality of the IC process (Jefford 
& Moore, 2008). The current informed consent process involves two major elements: 1) the 
patient's review of the informed consent document, and 2) extensive discussion between 
the patient and the health care team (shared decision-making). To date, studies aimed at 
improving the informed consent process have focused primarily on the first element by 
enhancing the content, format, or delivery of the consent document.  Examples include 
attempts to shorten consent forms (Davis et al., 1998), simplify language (Jefford & Moore, 
2008), and incorporate audiovisual elements (Ryan, McLaughlin, & Hill, 2008), none of 
which have been shown to reliably improve the quality of informed consent. These findings 
have led some authors to suggest that the crux of the consent process lies in the second 
element – the conversation between patient and consent specialist. How this conversation 
unfolds, however, is highly variable and depends on consent specialist/patient attitudes, 
provider skill level, and time constraints, among others. In other healthcare settings, 
decision aids (paper-based or multimedia) have proved highly useful in facilitating these 
complex discussions by prompting patients to articulate and clarify their decision-related 
values, and by providing a framework to weigh the pros and cons of each option within the 
context of these clarified values (Stacey et al., 2011). 
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Electronic consent (EC) has taken a front seat in the world of e-health technology as it 
pertains to research and care and will possibly become standard practice in consenting 
study participants as well as patients. There are several theoretical advantages of EC over 
standard consenting methods, including the following: 
 Improved education to study participants and patients 
 Improved decision-making by participants and patients 
 Better accrual rates 
 Greater efficiency in consent delivery by clinical staff 
 Waste reduction/cost savings 
 Participation/patients staying in the study to a conclusion 
 
Informing patients about oncology procedures, biobanks, and trials in a comprehensive but 
understandable fashion is both a challenge and an opportunity. A fundamental re-design of 
the informed consent process is needed, focused around three primary design principles: 
 Patient-centeredness, 
 Clinical practicality, and 
 Regulatory compliance. 
 
Based on these principles, I have identified an innovative EC platform that has the potential 
to become a treatment and research resource.  If successful, transitioning to EC has the 
potential to reduce disparities in cancer patient decisions about medical procedures, 
improve understanding among patients, and increase the willingness of patients to consent 
to procedures. 
 
Literature Review 
Previous attempts to enrich the IC process through the use of audio-visual content have 
yielded mixed results. Only four studies met inclusion criteria for a recent Cochrane review 
on this subject, highlighting the relative paucity of data in this arena and underscoring the 
authors’ call for further study. Similarly, incorporation of decision aids into the IC process 
for medical procedures has not been extensively studied. 
 
Several comprehensive recent reviews suggest that electronic or interactive multimedia 
approaches generally lead to measurably better patient understanding and improved 
knowledge, as well as a statistically significant improvement in patient comprehension of 
impending treatment(s) relative to standard paper-based or consultation-only methods. 
Studies cited in this review validate that patient comprehension and willingness to undergo 
treatments are greatly enhanced through interactive audio-video based methodologies. 
Other recent studies have suggested that videos used during the consent process may 
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improve understanding of study procedures and that audio-visual interventions improve 
patient recall about healthcare procedures. 
 
Mahnke et al. set out to determine the best way to improve the consent process by 
collecting data from a community perspective on computer-based consenting approaches. 
This study also evaluated whether or not participants were empowered to make informed 
decisions about participating in research. Regarding informed consent functionality, this 
study explored various aspects of design and format including readability levels, computer-
based delivery, and comprehension (Mahnke et al, 2014). 
 
The tool was consistently delivered, self-paced, and interactive for more detailed queries 
about the content. Research staff would answer participant questions at any point during 
the consent, supplemented the computer-based consent, or any technical support needs 
that might have occurred.  The computer-based consent proved to be simple and 
understandable at low levels of literacy. 
 
Although one of the primary aims of this study was to establish benefits of community 
involvement in designing informed consents, it also demonstrated support for movement 
away from paper-based consenting and toward computer-based methods by improved 
comprehension and retention. 
 
In 2009, Bickmore, Pfeifer, and Paasche-Orlow conducted a study on a computerized 
consent method on low literacy subjects. Participants received the research consent form 
by the computer agent, which was then compared to a human and a self-study condition in 
a randomized trial. The subjects' responses to the consent tool were evaluated based on 
their level of health literacy (Bickmore and Paashe-Orlow, 2009). 
 
The study found that subjects with higher health literacy scored higher on comprehension 
than other groups. Additionally, participants were most satisfied and most likely to sign the 
consent form when delivered by computer regardless of their literacy level. Participants 
stated that they preferred the computerized consent because it was self-paced, they felt 
more at ease about re-asking questions, and they didn’t feel as insecure about their level of 
health literacy. The subtext here is that they didn't feel the sense of judgment that they 
would normally feel with the human-based consent process.  
 
While the majority of the existing research favors a shift toward electronic consents, a few 
studies reveal mixed conclusions about the difference between standard consent and 
electronic consents on patient comprehension and decision-making.  For example, Valenza 
et al. tested the efficacy of personalized informed consent generated through an electronic 
health record (EHR) and its impact on patient decision-making.  The study evaluated 50 fifty 
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patients that were split into 2 groups. One (control) received the standard consent and the 
second received a "SmartConsent”. The participants were evaluated after treatment based 
on demographics, decisional conflict, satisfaction, health literacy, and knowledge. The 
researchers concluded that, overall, there were no significant differences between the two 
methods of consent on decision-making and satisfaction. However, researchers also 
concluded that there was clear potential for electronic consents to enhance communication 
between the provider and patients (Valenza, 2014). 
 
A 2014 study on an informed consent tool that was developed to address low literacy and 
ease of use in an area where a malaria treatment trial was being planned in Gambia. 
Olanrewaju et al. developed a multimedia informed consent tool that integrated video, 
animations, and audio narrations.  Attempting to demonstrate increased comprehension, 
this study captured participant understanding by using a validated digitized audio 
questionnaire.  Researchers found that 70% of their sample felt that the consent tool as 
"clear and easy to understand" as compared to the standard consent. Their high scores on 
comprehension of adverse events, voluntary participation, and study procedures supported 
the subjective responses of the participants. Furthermore, "participants expressed 
satisfaction with the tools and wanted future studies to adopt them" (Olanrewaju, 2014). 
 
Researchers concluded that their newly developed consent tool was acceptable and easy to 
administer. Additionally, as compared to standard consent, the new tool proved effective in 
delivering and sustaining comprehension of study information. The results of this study 
showed a significant increase in recall and comprehension scores. The potential for practice 
effect was mitigated by the use of digitized close-ended questionnaires, multiple-choice and 
open-ended items that would prompt the truest measure of participant comprehension. 
 
The major findings of this study, and arguably the most meaningful, were that the tool 
reliably delivered the same information to participants without variation in content or 
method. This is critical when considering staff changes, varying skill levels, language and 
other related barriers that might impede comprehension. 
 
“However, the ultimate benefits of ensuring well-informed research participants through 
the use of multimedia intervention could, in addition to improving participants’ 
comprehension, protect their freedom to decide, and also potentially improve the quality of 
data and outcome of the research” (Afolabi et al., 2014). The authors conclude that nothing 
can replace person-to-person interaction. Therefore, the overall effectiveness of the tool 
and satisfaction of the participant depends on a combination of technology and human 
interaction. 
 
 
 
8 
 
Public Health Significance 
Each of the aforementioned studies evaluated a different technology or aspect that would 
impact the comprehension and retention of informed consent information. However, there 
is no current literature that explicitly explores the impact of a fully electronic consent 
application delivered via mobile technology for apheresis. Furthermore, there has been no 
study that addresses the utility of mobile devices in improving comprehension, retention, 
and decision-making as it pertains to cancer patients receiving apheresis. As some research 
has indicated, electronic consents can enhance communication between the provider and 
patients. However, the type of EC and platform upon which it is delivered is critical. The 
seamless integration of multiple communication aids into one device and proper 
organization of the content is where previous studies have fallen short in identifying a 
suitable replacement for SD. 
 
In considering whether or not to pursue the development or implementation of an EC 
solution into a research or medical treatment setting, one has to establish a real need and 
clear expected outcomes.  Informed consent is not just a signature line or arbitrary concept, 
it is a process of organizing and delivering complex information that can have severe 
impacts on a person's health.   As such, informed consent information contains medical 
content, operative producer descriptions, recovery explanations, risk warnings, treatment 
protocols, verbal discussions, and question/answer exchanges to verify understanding.  This 
is a process, not just a signature or a box to be checked.  This process is critical to the safety 
of patients and study participants as well as to the integrity of research and medical 
institutions. 
 
While function and benefits were discussed in the previous sections, the aim here is to 
establish and distinguish the unique value of EC when comparing it to the standard 
documents or static digital forms.  EC goes a step further than the standard document or 
static digital form by providing a browser-based algorithm that captures consent 
requirements, limitations, levels of comprehension, and retention thereby bridging the gap 
between a standard/static document and EC/dynamic interface. 
 
The use of the term dynamic is intended to establish the feature advantages of EC, which is 
to empower patients and study participants to actively engage in an informed, comfortable 
and confident way.  The central idea is to give patients and study participants a sense of 
control throughout the decision-making process as it relates to the course of their 
healthcare or study participation.  EC is conceptually distinct as it addresses the modalities 
through which a participant's choice is enabled rather than just the use of mobile 
technology to capture a signature. 
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It is important to note that the EC process is not intended to replace patient-provider or 
participant-researcher interaction.  Quite the opposite, the personal interaction is necessary 
to facilitate better healthcare delivery and improved public health outcomes.  Furthermore, 
one of the goals of EC is to enhance patient confidence and participation in healthcare and 
research settings, which cannot be achieved independently from interaction with medical 
and research staff. 
 
EC, in concept and utility, is intended to ensure that patients understand the full context of 
their healthcare or research participation decisions. As such, the methods used to capture 
informed consent can influence decision-making.  For example, if consent is obtained at a 
hospital, patients may be biased by the sense of urgency of a scheduled procedure.  
Consequently, they could begin to simply checkboxes or opt-out altogether to avoid the 
decisional anxiety.  Another example can be found in how the inherent complexity of 
medical or technical information is conveyed may influence a patient's or study participant's 
ability to make an informed decision. These examples set the stage for situations where 
some individuals may defer the decision-making to those who appear to be in authority or 
opt-out entirely. 
 
The use of EC has typically been met with a measure of resistance in medical procedures 
and clinical trial settings.  The concern in these settings is establishing certainty around 
comprehension and retention of complex information.  As such, conventional categories for 
EC have been primarily for browser-based studies and when sending bio-specimens via 
mail.  However, as noted previously, there are advantages to using EC:  
 Freedom to complete in any setting 
 Reduced literacy and decisional anxiety 
 Multimedia options lead to more engagement 
 
Cost of Design and Implementation of EC Technology 
In a medical or academic setting, the costs related to any project are often very limited in 
resources and time.  As it pertains to software or application development, this can be 
particularly challenging, as most people aren't familiar with the process, costs, or in 
possession of the necessary technical expertise.  Medical and academic institutions 
generally assign technical teams and dollars to specific projects based on daily operational 
needs.  Exploratory or experimental technical project is generally not considered a high 
priority or likely to yield a high return on investment.  This means resources for building a 
software application may need to be secured through some form of private investment, 
grant, or research funding. 
 
The EC development project began as collaboration between physicians, project managers, 
and researchers at MD Anderson Cancer who recognized an opportunity to improve the 
 
10 
 
effectiveness and efficiency of the consent process in clinical trials as well as broader 
application to medical procedures. 
 
The initial project was funded by a grant for approximately $12,000.00.  With this funding, 
the team was able to pay for the physicians' and researchers' time.  Of course, this funding 
was quickly consumed by the effort to design content and technical requirements.  
However, this prepared the team to identify external partners to begin development 
discussions based on clear requirements.  Requirements are critical for two reasons: 1) they 
ensure that you develop a product that meets the needs of your project and 2) ensures that 
the development team more accurately and efficiently produces the desired application. 
 
The cost of software development will depend on how sophisticated the features are and 
the intended use of the application. This is an important consideration when defining what 
an application should and how the interface should function.  Arguably, a static electronic 
form is cheaper and is commonly used.  Essentially, it is a form that allows you to 
checkboxes and sign it on a mobile device. A static electronic form replaces paper, reduces 
time and waste. However, it does nothing to enhance a patient or study participant's 
experience. In essence, a static form on an electronic device is the same as paper.  That 
notion forms the underpinning for why developing a dynamic and interactive application 
would be more beneficial in a clinical setting. A dynamic form allows users to interact with 
the content. The task for the project team evolved into developing an application that 
achieved a few specific aims (enhancing comprehension, retention, lower anxiety) and 
ensuring that it possessed the necessary features to accomplish them. 
 
As noted, the project team developed content around a clinical trial using validated scales 
and defined aims that were to be achieved by the application.  While the project team had 
ample clinical and scientific experience, they were in deficit of software development 
experience.  The other concern was that the original study that funding the project had 
closed and the funds were depleted.  The project would not be able to proceed without 
additional funding. 
 
The team began a search for companies and startups with expertise and willingness to 
engage with the team at no cost.  This meant there needed to be the promise of a different 
acceptable currency.  In this case, the alternative currency was the potential commercial 
expansion of a highly customized medical software application and/or publication credits.  
The project was fortunate to find DrugDev.  DrugDev provides sponsors, CROs, and sites 
with solutions that transform clinical research through collaboration, standardization and 
beautiful technology experience. DrugDev agreed to provide a customized prototype for use 
in clinical trials or medical procedures if the team would share the performance data and 
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credits for publication of research findings.  During the engagement with DrugDev, the team 
learned that the following steps are critical to engagement with software developers: 
 
1) Defining Requirements 
The project team must have a defined list of requirements that establish what the 
final project should do for the intended users.  This step is where the project team 
and developers engage in detailed discussions about the intended audience, 
intended use, appearance, outcomes, and desired features of the application.  If 
there is no shell or prototype, information gathered during this step is when they are 
created. 
 
2) Design 
If there is no prototype, one is designed based on the requirements.  If there is a 
prototype or shell, then the requirement is used to customize the functionality of 
the existing tool or application.   This usually means a deeper focus on what the user 
interface and experience should be.  That is, how will the application look and feel, 
how easy is it to use, and what will distinguish it from similar applications. 
 
3) Development and Testing 
Once the prototype has been created or refined, it must be programmed to function 
as intended.  Once programmed, it must be tested to ensure that the coding follows 
the necessary protocols to deliver a seamless experience for the user.  Testing 
happens by the programmers (alpha) then by a second external group (beta).  Lastly, 
the project gets to test the application and validate that all of the requirements have 
been met and that the application functions as intended. 
 
4) Go-live/Launch 
If any issues are detected, the technical team will fix any coding issues and retest.  
Once all issues have been addressed and final tests have been completed, the 
application is loaded to encrypted servers and may available for use. 
  
Generally, software development can be expensive depending on requirements and 
potential maintenance. On average one can expect to conservatively pay $40,000 (see 
below cost table).  A $40,000 project is generally considered to be a small team (developer, 
designer, programmer) working for about 2 months.  Keep in mind that this does not 
include the salary of the project team or account for sweat equity. 
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Table 1 Market Costs of EC Design 
                    
           Source: (Diceus, 2019) 
 
From a commercial industry standpoint, the challenge is convincing sponsor or grant 
lending entities that the return on investment (ROI) outweighs the initial burden and 
expense of implementing the new technology.  This skepticism is shared by healthcare 
organizations that are reluctant about deploying IT resources to build their own EC tools.  
The same hesitation plagued many hospitals when they considered incorporating electronic 
health records into their operations.  It is a challenge to justify the high upfront costs, 
additional training, maintenance, and extended start-up timelines required when the 
demonstrated benefits have not been substantially documented. The 2017 CRF Health 
study found that the clinical research professionals’ perceptions about the high cost and 
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uncertain ROI have prevented many companies from becoming early adopters of EC, 
telehealth, and previously EMR solutions. (Sather, 2018) 
 
Developers, clinicians, and researchers recognize that EC enables better engagement with 
study participants and patients through personalized portals where information may be 
individually tailored. Despite the known benefits of multimedia tools to enhance delivery of 
informed consent information, demonstrating the ROI of EC has been stymied by the 
limited available data.  “While EC could save monitoring time, since documents are 
managed electronically, and there are potential savings if the tool can reduce protocol 
deviations, those types of benefits are difficult to quantify. Similarly, better patient 
comprehension of study requirements could help reduce participant drop-out rates, which 
could have a significant impact on study cost and data quality, but the cost associated with 
that outcome would be difficult to measure.” (Sather, 2018) 
 
Investors remain recalcitrant because there is a lack of clear, standardized and 
comprehensive policies surrounding EC.  Patients and clinicians use portals to access 
electronic health records, which establish a digital environment that integrates patient-
related information and clinical study data.  Simultaneously, this creates a natural space for 
EC to enable information to be conveyed in a digital environment with which the patient or 
study participant is already familiar.  
 
Basic clinical appointments now involve preregistration.  Future research studies could 
involve online registration or prescreening. Online EC enables study enrollment criteria to 
be compared with prospective study participant medical history based on the information 
they choose to provide.  This suggests that prospective study subjects will be enabled to 
identify studies that are best suited to their interests or medical needs.  Big data 
organizations, like IBM, have already begun to partner with large healthcare facilities to 
integrate medical records with EC to assist clinicians with determining which studies may 
best serve their patients and automatically allow them to consent remotely.  This puts the 
power of the decision-making at the patient’s fingers as well as providing amble time to 
form questions or conduct online research.  This level of early patient or study participant 
engagement promotes lower decisional anxiety, better comprehension, and comfort with 
the study or operative procedure.   
 
From a research industry standpoint, EC has gained a lot of attention for use in clinical 
trials.  It offers the potential to address patient recruitment and retention challenges that 
paper forms cannot.  Keeping pace with the cultural evolution that moves in lockstep with 
technology means developing the necessary tools to securely capture the patient or study 
participant consent. Obtaining proper consent is critical regulatory compliance 
requirements, data integrity, human subject protection, and expenses. EC offers a way in 
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which the process can be presented so it decreases the risk of insufficient or unreliable 
consent. 
 
While the movement has been slow among research groups as there remains a great deal of 
policy guidance and research community acceptance, there are several benefits as it relates 
to clinical and medical procedures as outlined below: 
 
Table 2 Research Benefits of EC  
Benefits Description 
Convenience 
  
Complete the consent in a comfortable setting or in 
advance to arriving on site. 
Access to more information 
Multi-media/dynamic interfaces offer links to 
additional resources for informed decision-making. 
Engagement  
EC capture user questions that aid clinicians, 
researchers, and participants with getting questions 
answered.  
Retention 
Intuitive/interactive EC promotes participant 
compliance and retention through better 
comprehension. 
Accrual 
Enhanced convenience and understanding of what 
they’re signing impacts enrollment rates. 
Comprehension 
By verifying that participants comprehend consent 
information through built-in knowledge tests, EC 
supports better information understanding.  
Collaboration 
  
EC makes it easy for sponsors, sites, and IRBs/IECs to 
work together efficiently. 
Reach 
The ability to consent participants remotely enables a 
wider participant base to be reached. 
Costs 
EC improves recruitment, reducing site consent time, 
and lowers the risk of litigation and related expenses,   
 
While these benefits highlight some clear advantages, there are also some real precautions 
to be considered as both clinical trials and research are complex.  Moreover, the nature, 
risks, and severity of different studies present unique challenges.  The following are a few 
key considerations that, while EC may inherently address, must be anticipated and planned 
for: 
 Data security -Verify that the EC system protects patients' private health 
information and be clear about whom ultimately is liable for security. 
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 Processes - Be clear and standardized about the protocol around how the EC will 
be administered as well as how training will be provided to research or medical 
staff. 
 Inspection readiness - Have a clear process that allows access to the EC system if 
requested by the regulatory authorities during an inspection.   
 
Ethical Consideration 
“Informed consent (IC) is essential for the ethical conduct of research and medical 
treatment. The overarching goal of the IC process is to guarantee that the patient acquires a 
sound understanding of the purpose, risks, and methodology of a clinical trial and/or 
medical procedure.” (Abujarad et al., 2018)  EC is seeking to facilitate this essential element 
of research through its adherence to Federal guidelines while simultaneously enhancing 
patient comprehension, retention, and decisional satisfaction.  By extension, the desired 
outcomes include lower costs and reduced risks to patients and study participants. In 
regards to the expert consensus on EC, “the Joint Commission reported that, “among 
patients who sign an IC form, 44% do not understand the nature of the procedure to be 
performed, and 60-70% did not read or understand the information contained in the form. 
Thus, the Joint Commission urges reform given the poor potential of the IC process in 
achieving patient understanding.” (Abujarad et al., 2018) 
 
Objectives 
The primary objective of this study is to determine whether patients who receive the 
interactive electronic consent (IEC) have a better understanding of apheresis compared to 
those who receive the usual standard document (SD). There are two primary endpoints, 
each measured using the Quality of Informed Consent (QuIC) index at the time of their first 
randomization: their knowledge of the various facets of the procedure, including the 
purpose of treatment and their rights (Part A), and their understanding of the IC form (Part 
B). Secondary endpoints include the effect of EC vs. SD on decisional conflict, patient 
satisfaction, and anxiety, as well as preferences between the SD and electronic IC and 
whether participants who have the EC are more likely to have the procedure. 
To achieve this objective, the specific aims of the study are: 
 
 Aim 1) Obtain post-SD and post-EC comprehension, satisfaction, anxiety, and 
decisional uncertainty in patients who received SD and EC information. 
 Aim 2) Compare post-survey and post-EC comprehension, satisfaction, anxiety, 
and decisional uncertainty in patients who received SD and EC information. 
 
The primary hypotheses was that compared to the SD, the EC would: 1) improve treatment 
comprehension among participants currently or recently scheduled for apheresis; 2) reduce 
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decisional uncertainty among participants currently or recently scheduled for apheresis; 3) 
reduce anxiety, and 4) increase satisfaction. 
 
 
METHODS 
Walk-in apheresis donors were approached as they entered the apheresis clinic.  
Interested subjects then had a consent interview with the Research Nurse or Research Data 
Coordinator in a private area (i.e., patient education/consultation room). During this 
interview, those study subjects learned about the parameters of this study and were 
consented to participate.  Subjects who agreed to participate signed a protocol-specific 
informed consent that did not include any consent information about the procedure and 
were randomized to Group A (SD) or Group B (EC). 
 
For subjects who were randomized to the EC group, the visit began with the Research Nurse 
or Research Data and the subject reviewing how to navigate the EC modules using the iPad.  
Then, the subjects were left to review the apheresis informed consent material and 
complete the assessments on the iPad. After the assessments were completed, the EC 
subjects had the option of meeting with the clinician to discuss any questions or ambiguities 
they identified in the consent content.  Subjects randomized to the SD arm met with the 
clinician to briefly discuss the apheresis process and were given the SD consent form.  After 
reviewing the SD form, the subjects completed the assessment and engaged in standard 
discussions with the research nurse and clinician. The two groups received the same 
informed consent content, however group A received the SD only and Group B received an 
iPad with consent information. 
 
Study Subjects 
Those who chose to participate underwent simple randomization (Kim & Shin, 2014), given 
the small sample size.  Group A was given the SD informed consent and Group B was 
provided with an iPad that was preloaded with informed consent modules.  Demographic 
data was captured from surveys that included signatures, age, ethnicity, education level, 
and gender. All measured covariates were balanced by randomization.  The following five 
standardized measures were assessed per participant (Quality of Informed Consent scale, 
Decisional Conflict scale, Decision Making Process Scale, and State-Trait Anxiety Inventory). 
 
Eligibility criteria include: 
1) Age >= 18 years 
2) Ability to speak, read and understand English  
3) Apheresis donor at MD Anderson Cancer 
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MD Anderson Granted IRB Approval for this study per collection of survey responses from 
actual and potential apheresis donors.  This study was considered low risk in that it did not 
expose patients to health risks.  Furthermore, approval was granted because the risk to 
patient privacy was also very low.  IRB included permission to collect patient demographics 
(age, race, gender, and education).  All survey responses were captured and stored on 
secure servers.  No participant identifiers were used or retained or this study. 
 
STUDY DESIGN  
Subjects were alternatively assigned to either the EC or SD arms. Demographic data was 
captured during the interview that included age, ethnicity, education level, and gender. 
Data on whether or not apheresis was collected was not collected because it is not needed 
for the evaluation. 
 
The iPad was configured in presentation mode with the appropriate EC module.  Group B 
subjects viewed the EC module in the clinic using the iPad. The EC modules contained no 
patient identifiers and no personal health information was stored on the iPad.  After 
reviewing the EC module, the subjects engaged in standard discussions with the research 
nurse and treating physician. 
 
Of note, the study did not include any explicit changes to the format, content, or structure 
of patient-clinician discussions. As discussed above, the patient-clinician discussion is of 
critical importance to the overall IC process. While this is an area to examine in future 
studies of EC, it was not an area of inquiry for the current study. Subject surveys were 
administered at the end of the consent process via the iPad. The device did not store any 
patient data to ensure privacy protection and HIPAA compliance. The data collected 
transferred automatically to encrypted servers. 
 
 
EC 
There was a short video on time required and how to navigate the EC, which was delivered 
by the clinical staff to EC arm. 
 
Within the EC software, the patient/user intuitively controls the interface with functions 
including swipe-to-turn pages, interactive illustrations, and a clickable in-line glossary. 
Embedded videos allow for participants to hear about key features of the procedure directly 
from the physician. A notepad feature allows participants to save, print, or email questions 
to the research team. A unique “tell me more” feature allows participants to individually 
titrate the information stream by clicking on specific areas (e.g. “Tell me more about side 
effects” or “Tell me more about how the treatment works”). A productive collaboration 
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with the MD Anderson Office of Patient Education and feedback from our community 
oncology colleagues led to significant language and interface improvements. 
 
MEASURES AND INSTRUMENTS 
The following scales selected for this study have been standardized for use in the clinical 
trial and medical procedure settings.  Although other scales, like the Deaconess Informed 
Consent Comprehension Test (DICCT), Brief Informed Consent Protocol (BICEP) Basic 
Investigator Questionnaire (BIQ), and the Modular Informed Consent Comprehension 
Assessment (MICCA), they weren’t used as frequently in research which was considered as 
less trusted in studies pursuing similar aims.  However, the scales selected for this study 
have shown good internal reliability and test-retest reliability (Stalmeier, et al., 2004).  
Surveys were administered to study participants as described above employing the 
following five standardized measures, each lasted approximately 20 minutes: 
 
 Quality of Informed Consent scale (QuIC)   
Comprehension was assessed using the validated Quality of Informed Consent 
(QuIC) scale. The QuIC is a valid and reliable questionnaire that is easy to use and 
designed to reduce researcher and subject biases.  It’s designed to measure actual 
(objective) and perceived (subjective) understanding of consent information (Joffe et 
al., 2001). It can also be used in the initial training of clinicians and study 
participants.  
 
The QuIC scale consists of two parts: Part A assesses objective (or actual) 
understanding of the procedure and Part B assesses perceived (or subjective) 
understanding of the procedure. We developed a procedure-specific QuIC part A 
and use a standard QuIC part B. The QuIC scale has 10 items and yields two 
continuous scores, one for objective understanding and one for perceived 
understanding. (Appendix A.) 
 
 Decisional Conflict Scale (DCS) 
The DCS measures the degree of uncertainty of patient or research subject decision-
making. The DCS measures 5 dimensions of decision-making across personal 
perceptions of: 
a. Uncertainty in choosing options; 
b. Modifiable factors contributing to uncertainty such as feeling uninformed, 
unclear about personal values and unsupported in decision making; and 
c. Effective decision making (in full version) such as feeling the choice is 
informed, values-based, likely to be implemented and expressing satisfaction 
with the choice. 
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This instrument was selected because studies validating it revealed that decisional 
conflict could be lowered with decision-supporting interventions (Kim & Shin, 2014). 
Information about options, benefits, risks, and side effects empowers patients and 
study subjects to make an informed decision. 
 
This is a commonly used outcome measure in studies of patient decision aids, the 
16-item DCS was adapted for the decision about participating (Garvelink, et al., 
2019). The scale includes 5 subscales: Uncertainty subscale (feeling assured and 
clear about the choice), Informed subscale (feeling informed about the options, 
advantages, and disadvantages), Values Clarity subscale (importance of advantages 
and disadvantages), Supported subscale (having enough support, advice, and lack of 
pressure), and Effective Decision subscale (being satisfied with the decision and 
planning to follow through). (Appendix B.) 
 
 Satisfaction with Decision Scale (SWD)  
Patient satisfaction was measured using the ten-item Satisfaction with the Decision-
Making Process Scale. The SWD scale measures satisfaction with health care 
decisions. This scale was selected because it has excellent reliability and validity 
(Holmes-Rovner, et al., 1996). The SWD scale captures satisfaction with the health 
care decision at the time when a decision has been made but the consequences 
have not yet occurred in medical treatment situations. The brief scale provides an 
efficient measure that can be easily used in healthcare settings to evaluate decision-
assisting technologies or patient-provider interactions aimed at involving patients in 
decision-making. (Appendix C.) 
 
 State-Trait Anxiety Inventory (STAI)  
Anxiety levels were assessed using a 6-item short form of the State-Trait Anxiety 
Inventory (STAI). The STAI is the definitive instrument for measuring decisional 
anxiety in adults (Metzger, 1976). It distinguishes between a brief state of anxiety 
and the more chronic condition of "trait anxiety (depression)". The inventory’s 
simplicity makes it ideal for evaluating individuals with various educational 
backgrounds. (Appendix D.)  
 
 The utility, design, and acceptability of the EC were assessed via a purpose-designed 
questionnaire for post-EC participants only. This survey includes patients' ratings of 
the following: 1) ease of use/interface, 2) balance of the presentation related to the 
options of participating or not participating in the procedure, 3) clarity of the 
information presented, 4) length of the EC, 5) the amount of the information 
included in the EC, and 6) preference for traditional consent vs EC.  (Appendix E.) 
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Note: If anxiety is detected or communicated by the patient, normal protocols will be 
followed. The study would be stopped, clinical staff would be alerted, and a nurse or 
physician would evaluate the patient. 
 
Data Analysis 
Scales, as described in the design section, were used based on the suitability for this study 
and alignment with federal requirements.  Responses from both groups were captured in a 
secure server and downloaded to SAS 9.4 (SAS Institute, Cary NC).  Both total group scores 
were summed, assigned an average score against which the groups were compared. Mean 
scores were compared using the two-sample t-test with a significance level of 0.05. The 
following describes the questionnaires and how they were calculated: 
 
 Quality of Informed Consent (QuIC)  
o QuIC Part A (range 0 – 100, a high value indicates better understanding) had 
18 questions. For each question, correct answers are assigned a score of 100 
points, incorrect answers are assigned a score of 0 points, and "unsure" is 
assigned a score of 50 points. The final scores are obtained by averaging the 
scores of all completed questions. 
o QuIC Part B had 13 questions (range0 -100, a high value indicates better 
understanding). The responses are first averaged to obtain raw average 
(range, 1-5), then final score = (raw average - 1)*25 (Joffe et al., 2001). 
 
 Decisional Conflict Scale (DCS)  
o DCS had 16 questions (range 0 – 100, high value indicates high decisional 
conflict). The total score is obtained according to the User Manual:  
 0 = “strongly agree”; 1 = “agree”, 2 = “neither agree nor disagree”, 3 = 
“disagree”; 4 = “strongly disagree”. 
 Sum scores of all 16 questions; 
 Divided by 16; 
 Multiplied by 25 
 
 
     Ease of Use 
o EC survey had 8 questions 
 4 = “Excellent”; 3 = “Very good”, 2 = “Good”, 1 = “Fair”; 0 = “Poor”. 
 Sum scores of all 8 questions; 
 Divided by 8; 
 Multiplied by 25 
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    Satisfaction with Decision Survey  
o 6 questions (range 0 – 100, high value indicates high satisfaction) 
 4 = “strongly agree”; 3 = “agree”, 2 = “neither agree nor disagree”, 1 = 
“disagree”; 0 = “strongly disagree”. 
 Sum scores of all 6 questions; 
 Divided by 6; 
 Multiplied by 25 
 
    State-Trait Anxiety Inventory (STAI) 
o 17 questions. To calculate the total STAI score (range 20 – 80, a high value 
indicates high anxiety): 
 Reverse scoring of the positive items so that 1=7, 2=6, 3=5, 4=5, 5=3, 
6=2 and 7=1; 
 Rescale the score by multiply 4/7 so that the scale of the study, 1-7 
becomes the standard 1-4; 
 Sum all 17 scores; 
 Multiple total scores by 20/17. 
 
To analyze the results of our experiment, we used two sided, two-sample t-tests with a 
significance level of α=0.05.  All computations were performed using SAS 9.4 (SAS Institute, 
Cary NC). 
 
RESULTS 
Other studies have shown that “females have higher donation rates than males among 
African Americans and Hispanics. For whites, the blood donation rate for males exceeds 
females beginning at age 30" (Shaz et al., 2011). Additionally, these studies have reveal that 
ethnic minorities are underrepresented in blood donation. 
 
In the study, there were a larger number of non-white female subjects with college degrees 
among the study participants.  Further analysis may be needed to determine to what extent 
these demographic characteristics may have influenced the responses to survey questions.  
 
 
 
 
 
 
 
 
22 
 
  Table 3  Subject Demographics 
Variable Value #(% of n) n(% of N) SD EC 
Gender Female 38 (66)  17 21 
 Male 20 (34) 58 (100) 10 10 
Education Associate degree 6 (10)  4 2 
 Bachelor degree 23 (40)  16 17 
 Graduate degree 3 (5.2)  2 1 
 High school degree or equivalent  11 (19)  6 5 
 Less than a high school degree 5 (8.6)  2 3 
 Some college but no degree 10 (17) 58 (100) 5 5 
Race Asian 4 (6.9)  2 2 
 Black or African-American 13 (22)  6 7 
 From multiple races 4 (6.9)  1 3 
 Latino/Latina 14 (24)  7 7 
 White 23 (40) 58 (100) 13 10 
Age 25 to 34 18 (31)  9 9 
 35 to 44 24 (41)  14 10 
 45 to 54 5 (8.6)  2 3 
 55 to 64 11 (19) 58 (100) 5 6 
Group Electronic consent  28 (48) 58 (100)  28 
 Standard document 30 (52)  30  
 
Table 3 illustrates the subject demographics for the study.  Although the larger proportions 
of the population were female, white, college-educated, and between the ages of 35 and 
44, it is not immediately clear what impact that had on their responses to the surveys.  
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           Table 4 Summary of Survey Scores 
Variable N Mean ± SD 
25/50/75                   
Percentile 
STAI_score 58 37.2 ± 13.5 26.7/38/48.6 
QuIC A_score 58 67.3 ± 10.3 60.4/66.7/75 
QuIC B_score 58 69 ± 23 49.5/69.2/90.9 
DCS_score 58 34.7 ± 23.5 19.1/27.3/57.8 
SWD_score 58 60.4 ± 26.9 37.5/68.8/75 
iPad_score 28 77.8 ± 21.4 53.9/78.1/100 
 
For STAI, subjects who score 20 to 40 fall within normal or tolerable limits, 40 to 60 
represent mild problems, and 60 to 80 are severe.  As shown in Table 4, the subjects from 
this study average 37.2, which is normal or tolerable.   
 
The QuIC scoring was based on a 0-100 scale.  Ideally, patients scoring higher or closer to 
100 reflected a higher Comprehension and understanding of the informed consent content.  
The average score was 67.3 meaning the subjects had an acceptable level of 
Comprehension and understanding. 
 
The DCS scoring was also based on a 0-100 scale.  In this, it would ideal for the subjects to 
score closer to 0.  This would indicate lower decisional conflict or greater comfort with the 
decision to participate in a given study or procedure.  The average score was 34.7, which 
represents low decisional conflict. 
 
The Satisfaction scoring was based on a 0-100 scale.  Ideally, patients scoring higher or 
closer to 100 reflected a higher satisfaction with the consent process. The average score 
was 60.4 meaning the subjects had an acceptable level of satisfaction with the informed 
consent process. 
 
The EC survey was a subjective questionnaire to determine how easy the app was for the EC 
group to use and provide insight into what improvement might need to be made.  Ideally, a 
higher score from 0-100 would subject the device and the app performed well.  This group 
scored an average of 77.8, which suggests that the device and app performed well. 
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Table 5 Comparisons of the 5 scores 
 Standard Document Electronic Consent  
Variable N Mean ± SD 
25/50/75                            
Percentile N Mean ± SD 
25/50/75                            
Percentile P 
STAI_score 30 40.6 ± 13 28.2/45.4/51.8 28 33.5 ± 13.3 23.9/30.3/40.8 .039 
QuIC (A)_score 30 62.1 ± 8.8 54.9/63.9/69.4 28 72.8 ± 8.99 66.7/72.2/77.8 <.0001 
QuIC (B)_score 30 54.7 ± 18.8 39.9/51.9/69.2 28 84.2 ± 16.6 71.6/88.5/100 <.0001 
DCS_score 30 47.3 ± 20.7 27.7/53.9/63.3 28 21.2 ± 18.3 2.34/25/26.6 <.0001 
SWD_score 30 50 ± 22 29.2/41.7/70.8 28 71.4 ± 27.6 67.7/75/97.9 .001 
 
Table 5 illustrates that the EC group outperformed the SD group in each survey, which 
suggests that there is a significant benefit to the patient when using the electronic consent. 
P values computed with a t-test. 
 
Table 6 Pearson Correlation Coefficients 
 STAI_score QuIC A_score QuIC B_score DCS_score 
QuICA_score -0.39 
0.0025 
 
 
  
QuICB_score -0.38 
0.0033 
0.71 
<.0001 
 
 
 
DCS_score 0.40 
0.0017 
-0.70 
<.0001 
-0.86 
<.0001 
 
 
SWD_score -0.43 
0.0007 
0.43 
0.0008 
0.57 
<.0001 
-0.63 
<.0001 
The first number of each cell is the Pearson correlation coefficient and the second number is the p-value. For 
example, the correlation between the STAI score and QuIC (A) score is -0.39.  
 
Table 6 indicates that the 5 instruments were highly correlated.  The following highlights the 
specific correlations: 
o High anxiety score was associated with a worse understanding of consent 
(Pearson = -0.39 and -0.38 to QuIC Part A and B. The p-values were 0.0025 
and 0.0033 respectively), high decisional conflict (Pearson = 0.40. The p-value 
was 0.0017) and the low satisfaction score (Pearson = -0.43. The p-value was 
0.0007) (See the first row of Error! Reference source not found.). 
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o Poor understanding of consent was associated with high decisional conflict 
and low satisfaction scores (See the second row of Error! Reference source 
not found.). 
o The high decisional conflict was associated with a low satisfaction score (See 
the third row of Error! Reference source not found.).  
 
DISCUSSION 
Informed consent for public health research participants can be complicated by 
comprehension, anxiety and decision-making issues.  Uncertainty around the risks or 
aspects of complications and recovery also fuel confusion or hesitation in decision-making.   
The complexity of informed consent information and, in some cases, the conditions under 
which it's presented can interfere with the comprehension and retention needed to make 
informed decisions.  These concerns are common in public health research settings and 
have to be accounted for when planning a study.  As previously described, the EC solution 
aims to mitigate these types of concerns.  In the public health context, the application 
specifically targets reducing the likelihood that the informed consent process results in a 
decision that negatively impacts the study participant or the research.  The following are 
common perceptions of study participants about informed consents: 
 Time-consuming and cumbersome – While the EC cannot alone promise to 
eliminate this concern, it was designed to be flexible.  The value of its flexible 
design is that it can be altered or customized based on the nature of the 
research or operative procedure so that it provides a tailored experience for 
each setting. 
 
 Content is too complex or hard to read – Literacy levels vary across various 
demographics.  As such, the literacy level for the targeted community must be 
considered during the design phase, as does the prevailing spoken language.  
Using the standard document approach can make printing, revising, filing, and 
retrieving documents costly.  EC virtually eliminates this as a concern and allows 
language conversation to happen more easily.   
 
 The study setting was suboptimal – When utilizing a standard document consent, 
it is common for there to be a lengthy discussion between the participant and 
someone from the research team.  This requires a suitable space and lots of 
time.  That dynamic is often costly in time, staff resources, and space.  The EC is 
designed with interfaces that respond to likely questions and store others to 
reduce the time both a room and a researcher may be needed.  
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 Couldn't relate to the content – The nature of static or standard documents is 
that you must read it in a manner in which it is provided.  Unfortunately, not 
everyone learns the same way or relates to information in the same manner.  
The EC addresses this by incorporating multimedia tools with educational 
material to present the information in a more engaging and accessible fashion. 
“Multimedia education use has shown promise among physical and behavioral 
health patients with increased understanding, comprehension and interest 
towards treatment and care.” (Bennett, Aronson, Guarino, Bania, & Marsch, 
2016) 
 
Similar to research, hospitals can also benefit from EC.  Specifically, hospitals can see 
improved patient safety, patient satisfaction, and quality of care.  As noted above, medical 
settings must keep pace with patients that have more sophisticated expectations as a result 
of access to vast amounts of information from the internet.  They expect faster and larger 
amounts of information about the diagnosis they receive and procedures for which they are 
prescribed.  Moreover, patient and research study participants are entitled to fully 
understand what they can expect following any treatment regime, recovery experience, or 
lifestyle changes they may have to make. 
 
Hospitals may also experience administrative benefits when incorporating EC into their 
operations.  Specifically, the may see: 
 
 Improved Informed Consent Management - EC offers digital signature capture to 
ensure the validity of the consent documents. 
 
 Reduced Transcription Time and Errors – Paper handling, filing, and storing is 
virtually eliminated when the documents are digitized. 
 
 Greater Regulatory Compliance - The use of EC applications enables greater 
compliance with Federal, state regulators and other requirements. 
 
As mentioned in the literature review section, previous studies to evaluate and improve the 
informed consent process yielded mixed results.  Each fell short in determine what specific 
modalities and in what combination would successfully improve informed consent.   Beyond 
the interactive features to deliver the research or medical consent information, the 
challenge was establishing a relationship between how it was delivered and 
comprehension.  While the previous studies suggest there were greater benefits to using 
electronic mechanisms to deliver informed consent, they failed to establish that it would 
lead to better patient understanding, retention, and satisfaction.  
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The survey results of this study revealed that the EC group had significantly less anxiety 
(STAI score), a higher understanding of the consent (QuIC Part A and Part B), less decisional 
conflict (DCS score) and higher satisfaction (Satisfy score) (see Table 3).   These findings 
ultimately support the study hypothesis that the EC had improved understanding and 
retention, reduced decisional uncertainty, lowered anxiety, and yielded greater satisfaction. 
 
CONCLUSION 
The chief finding is that the SD and EC groups differed in a statistically significant way in all 
of their responses to the surveys. The study also found a high degree of correlation 
between the instruments.   
 
The response returned "significant" (p < 0.05) values between SD and EC groups, which 
suggest that this difference is primarily attributable to the format employed to deliver the 
content. Specifically, the EC group performed better on each instrument.  It is not clear if 
demographics played a role in responses to the survey, that determination would require a 
follow-up study with a larger sample. 
 
Conventional standardized consent forms have significant deficiencies and errors. The new 
system of electronic informed consent is easy to deliver, legible and understandable.  
Furthermore, it assists researchers as well as providers with fully informing patients about 
the treatment, risks, benefits and alternative therapies, thereby supporting ethical and legal 
standards, and improving the quality of care. Standardized electronic informed consent 
should be the new standard of care. 
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APPENDICES 
Appendix A: Quality of Informed Consent 
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Appendix B: Decisional Conflict Scale 
 
Appendix C: Satisfaction with Decision Scale  
 
You have been considering whether to consult your health care provider about hormone-
replacement therapy. Answer the following questions about your decision. Please indicate to 
what extent each statement is true for you AT THIS TIME. 
 
Use the following scale to answer the questions.  
1 = strongly disagree 
2 = disagree 
3 = neither agree nor disagree  
4 = agree 
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5 = strongly agree 
 
() I am satisfied that I am adequately informed about the issues important to my decision. 
() The decision I made was the best decision possible for me personally. 
() I am satisfied that my decision was consistent with my values. 
() I expect to successfully carry out (or continue to carry out) the decision I made. 
() I am satisfied that this was my decision to make. 
() I am satisfied with my decision. 
 
Appendix D: State-Trait Anxiety Inventory (STAI)  
 
 
Appendix E: Utility, Design and Acceptability Questionnaire 
 
iPad Utility, Design, and Acceptability Questionnaire  
1. The quality of the VIDEO was…  
 Poor Fair Good Very Good Excellent 
2. The quality of the SOUND was...  
 Poor Fair Good Very Good Excellent 
3. The quality of the information/training was… 
 Poor Fair Good Very Good Excellent  
4. My comfort with using the device was…  
 Poor Fair Good Very Good Excellent 
5. The ease of moving through the content was… 
 Poor Fair Good Very Good Excellent  
6. The ease of reading the content was…  
 Poor Fair Good Very Good Excellent 
7. The ease of holding and interacting with the application and device was… 
 Poor Fair Good Very Good Excellent 
8. The explanation of how to use the device/application was...  
  Poor Fair Good Very Good Excellent 
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